Plasma PlGF as a Potential Biomarker in Ramucirumab‐Based Second‐Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial
International Journal of Cancer · 2026
DOI: 10.1002/ijc.70567 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Jurek Hille und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Hematology and Bone Marrow Transplantation With Section Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Ger…. Hauptthemen laut MEDLINE: Adenocarcinoma, Placenta Growth Factor, Biomarkers, Tumor, Stomach Neoplasms. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eily Lilly and Company, Margarete Clemens Stiftung, E.W. Kuhlmann-Stiftung.
Abstract (Originalsprache)
Antiangiogenic treatment with ramucirumab (RAM) is a standard second‐line option in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. However, reliable biomarkers are lacking. The phase II RAMIRIS trial compared RAM plus paclitaxel with RAM plus FOLFIRI (5‐fluororuracil, leucovorin and irinotecan) in this setting. We present the exploratory biomarker analysis evaluating placental growth factor (PlGF), carbonic anhydrase IX (CAIX), and tryptase. Plasma samples from 99 patients enrolled in RAMIRIS were collected at predefined timepoints (baseline, Cycle 2 Day 1, and Cycle 4 Day 1). PlGF, CAIX, and tryptase were quantified by ELISA. Associations with progression‐free survival (PFS) and overall survival (OS) were analyzed using dichotomized biomarker levels and Cox regression models. PlGF levels increased substantially under treatment, whereas CAIX showed a transient rise, followed by a slight decline, and tryptase remained stable. Elevated PlGF levels at baseline and early‐treatment (c2d1) were associated with shorter OS in univariate analysis (baseline HR u = 1.75; p = 0.020; c2d1 HR u = 1.69; p = 0.054). After multivariate adjustment, the association remained directionally consistent; although statistical support was retained only for c2d1 (baseline HR m = 1.41, p = 0.198; c2d1 HR m = 1.85, p = 0.030). CAIX and tryptase showed no consistent associations with survival. Elevated PlGF—particularly its early increase during RAM‐based therapy—was associated with shortened survival and may represent a dynamic marker of unfavorable prognosis in advanced gastric/GEJ adenocarcinoma. Given the exploratory nature of this analysis, these findings should be considered hypothesis‐generating and require validation in independent biomarker‐driven studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Hematology and Bone Marrow Transplantation With Section Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Department of Medicine III, TUM University Hospital, Technical University of Munich, Munich, Germany.
- The Frankfurt Institute for Clinical Cancer Research IKF GmbH, Frankfurt/Main, Germany.
- DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany.
- Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), & Deutsches Zentrum für Lungenforschung (DZL), Heidelberg, Germany.
ORCID-Profile: Jurek Hille, Thomas Ettrich
Förderung
- Eily Lilly and Company
- Margarete Clemens Stiftung
- E.W. Kuhlmann-Stiftung
- Hector II Stiftung
Zitieren
APA
Hille, J., Lorenzen, S., Pauligk, C., Gensch, V., Thuss-Patience, P., Goekkurt, E., Ettrich, T., Lordick, F., Bokemeyer, C., Müller, C., Reichardt, P., Sökler, M., Pink, D., Probst, S., Goetze, T. O., Al-Batran, S. E., Loges, S., & Janning, M. (2026). Plasma PlGF as a Potential Biomarker in Ramucirumab‐Based Second‐Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial. International Journal of Cancer. https://doi.org/10.1002/ijc.70567
Vancouver
Hille J, Lorenzen S, Pauligk C, Gensch V, Thuss-Patience P, Goekkurt E, et al. Plasma PlGF as a Potential Biomarker in Ramucirumab‐Based Second‐Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial. International Journal of Cancer. 2026. doi:10.1002/ijc.70567
BibTeX
@article{Hille2026,
author = {Hille, Jurek and Lorenzen, Sylvie and Pauligk, Claudia and Gensch, Victoria and Thuss-Patience, Peter and Goekkurt, Eray and Ettrich, Thomas and Lordick, Florian and Bokemeyer, Carsten and Müller, Christian and Reichardt, Peter and Sökler, Martin and Pink, Daniel and Probst, Stefan and Goetze, Thorsten O and Al-Batran, Salah E and Loges, Sonja and Janning, Melanie},
title = {Plasma PlGF as a Potential Biomarker in Ramucirumab‐Based Second‐Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.70567}
}
EUVIMED